MannKind Corporation (MNKD): What’s the Latest: New Insulin Inhaler, Rating Reiterated by Zacks, Matthew J. Pfeffer & More

Editor’s Note: MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Merck & Co., Inc. (NYSE:MRK)

For Diabetics, a New Insulin Inhaler Could Replace Shots as Early as 2014 (Businessweek)
The long promise of insulin that diabetics can inhale appears to be moving closer to the market. An inhalable insulin powder called Afrezza showed positive results for controlling diabetes in a late-stage clinical trial, the drug’s maker, MannKind Corporation (NASDAQ:MNKD), reported today. Pharmaceutical companies have been working on inhalable insulin for a long time on the theory that diabetics would prefer to puff on an inhaler than give themselves a shot. In 2007, Pfizer (PFE) stopped selling its Exubera insulin powder because of weak sales after less than two years on the market. Exubera never gained traction, largely because insurers wouldn’t pay for it, saying it was too expensive and didn’t work for many patients. Eli Lilly & Co. (LLY) and Novo Nordisk (NVO) both ended inhaled insulin research programs in 2008.

MannKind Corporation (NASDAQ:MNKD)MannKind Corp. Rating Reiterated by Zacks (MNKD) (Watch List News)
MannKind Corporation (NASDAQ:MNKD)‘s stock had its “neutral” rating reaffirmed by Zacks in a research report issued to clients and investors on Wednesday, AR Network reports. They currently have a $7.25 target price on the stock. Zacks‘ price objective points to a potential upside of 5.69% from the stock’s previous close. Zacks‘ analyst wrote, “MannKind’s second quarter 2013 net loss of $0.16 per share was narrower than the year-ago loss of $0.23 but wider than the Zacks Consensus Estimate of a loss of $0.15. We expect investor focus to remain on Afrezza.

Investors Purchase High Volume of MannKind Corp. Put Options (MNKD) (Watch List News)
Shares of MannKind Corporation (NASDAQ:MNKD) was the recipient of unusually large options trading activity on Monday. Traders acquired 11,596 put options on the company, Stock Ratings Network reports.This is an increase of approximately 114% compared to the average volume of 5,418 put options. In other MannKind Corp. news, CFO Matthew J. Pfeffer sold 10,000 shares of MannKind Corp. stock in a transaction that occured on Thursday, August 1st. The stock was sold at an average price of $8.00, for a total transaction of $80,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission.

Healthcare Stocks in Spotlight – MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Merck & Co., Inc. (NYSE:MRK) (Techsonian)
King Penny Stocks is an elite financial community for investors and traders alike who are looking to potentially gain financial freedom through the markets on undervalued companies and “in-play” momentum penny stocks. Today We bring special trend analysis of following stocks: MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Merck & Co., Inc. (NYSE:MRK). MannKind Corporation reported the gain of +17.93% to $8.09 in the mid-day trading session with the total traded volume of 31.37 million shares more than the average volume of 6.37 million. MNKD has market cap of 2.45 billion and its beta value stands at 1.41 times. MannKind Corporation (MannKind) is a development-stage biopharmaceutical company.

MannKind Diabetes Drug Tops Expectations in Study, Shares Soar (Fox Business)
Shares of MannKind Corporation (NASDAQ:MNKD) climbed 20% Wednesday morning after the company revealed positive late-stage trial results for its experimental diabetes drug. The Valencia, Calif.-based drug developer said two Phase III clinical studies for Afrezza, an ultra rapid-acting mealtime insulin therapy administered through MannKind’s next-generation inhaler, met their primary endpoints. The results “will form the basis of an amendment to our new drug application for AFREZZA, which we expect to submit to the Food and Drug Administration early in the fourth quarter of this year,” MannKind CEO Alfred Mann said in a statement.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!